ArriVent BioPharma (AVBP) Other financing activities (2023 - 2025)
ArriVent BioPharma's (AVBP) quarterly Other financing activities came in at $17000.0 in Q4 2025, up 105.67% quarter-over-quarter from -$300000.0 in Q3 2025.
ArriVent BioPharma (AVBP) Other financing activities (2023 - 2025) Analysis & Trends
ArriVent BioPharma has disclosed Other financing activities across 2 years of filings, most recently posting $17000.0 for Q4 2025.
- Other financing activities for Q4 2025 came in at $17000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was $70000.0 (changed N/A YoY), and the FY2025 annual result was $70000.0, changed N/A from the prior year.
- Other financing activities came in at $17000.0 for Q4 2025 at ArriVent BioPharma, up from -$300000.0 in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $1.3 million in Q4 2023 to a low of -$300000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | ArriVent BioPharma | 1.37 Bn | 1.37 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 17,000.00 |
| Dec 31, 2025 | 17,000.00 |
| Sep 30, 2025 | -300,000.00 |
| Sep 30, 2025 | -300,000.00 |
| Jun 30, 2025 | 303,000.00 |
| Jun 30, 2025 | 303,000.00 |
| Mar 31, 2025 | 50,000.00 |
| Mar 31, 2025 | 50,000.00 |
| Dec 31, 2023 | 1.34 Mn |
| Dec 31, 2023 | 1.34 Mn |